Follow the people · Insider
Michael Heltzen
Michael Heltzen files insider transactions with the SEC as a chief executive officer of Exozymes (EXOZ). We hold 2 disclosed purchases and sales filed since 19 November 2024, 2 of them in the last 90 days.
- Files forEXOZ
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure2 September 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 17 June 2025 — 26 August 2026Chief Executive Officer · Exozymes (EXOZ)8 Form 4 lines · source: SEC Form 4
- Filed 15 November 2024 — 17 January 2025Chief Executive Officer · Invizyne Technologies (IZTC)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
11 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 4 shares of ExozymesSEC Form 42 September 2026Common Stock · traded 26 August 2026 · filed 2 September 2026
- ▲ bought on the open market 251 shares of ExozymesSEC Form 42 September 2026Common Stock · traded 26 August 2026 · filed 2 September 2026
- ▲ bought on the open market 250 shares of ExozymesSEC Form 42 September 2026Common Stock · traded 26 August 2026 · filed 2 September 2026
- ▲ bought on the open market 250 shares of ExozymesSEC Form 42 September 2026Common Stock · traded 25 August 2026 · filed 2 September 2026
- ▲ bought on the open market 100 shares of ExozymesSEC Form 42 September 2026Common Stock · traded 25 August 2026 · filed 2 September 2026
- was granted 8,841 shares of ExozymesSEC Form 42 September 2026Common Stock · traded 19 August 2026 · filed 2 September 2026
- ▲ bought on the open market 1,040 shares of ExozymesSEC Form 42 July 2025Common Stock · traded 2 July 2025 · filed 2 July 2025
- was granted 235,817 shares of Exozymes (a derivative holding)SEC Form 420 June 2025Stock Options for Common Stock · traded 17 June 2025 · filed 20 June 2025
- ▲ bought on the open market 121 shares of Invizyne TechnologiesSEC Form 421 January 2025Common Stock · traded 16 January 2025 · filed 21 January 2025
- ▲ bought on the open market 1,767 shares of Invizyne TechnologiesSEC Form 421 January 2025Common Stock · traded 17 January 2025 · filed 21 January 2025
- ▲ bought on the open market 1,984 shares of Invizyne TechnologiesSEC Form 419 November 2024Common Stock · traded 15 November 2024 · filed 19 November 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.